Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
about
Clozapine treatment of refractory schizophrenia during essential chemotherapy: a case study and mini review of a clinical dilemmaFeasibility and safety of a reduced duration of therapy of colony-stimulating factor in a dose-dense regimen.Myeloid toxicity of cancer treatment.The Effectiveness of Febrile Neutropenia Prophylaxis with Lipegfilgrastim in Routine Clinical Practice.Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia.Reliable, accurate determination of the leukocyte differential of leukopenic samples by using Hematoflow method.A non-interventional study of biosimilar granulocyte colony-stimulating factor as prophylaxis for chemotherapy-induced neutropenia in a community oncology centre.How many neutrophils are enough (redux, redux)?Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.Pegfilgrastim: a review of the pharmacoeconomics for chemotherapy-induced neutropenia.Pharmacoeconomics of granulocyte colony-stimulating factor: a critical review.Lipegfilgrastim for the prophylaxis and treatment of chemotherapy-induced neutropenia.A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal CancerInterpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.Impact of recommended weight-based dosing of granulocyte-colony stimulating factors in acute leukemia and stem cell transplant patients.A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study.Evaluation of factors associated with prolonged hospital stay and outcome of febrile neutropenic patients receiving chemotherapy: 70 cases (1997-2010).The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.Toxicity of docetaxel, carboplatin, and trastuzumab combination as adjuvant or neo-adjuvant treatment for Her2 positive breast cancer patients and impact of colony-stimulating factor prophylaxis.Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia.Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer.Comparative Diagnostic Performance of the Granulocyte and Neutrophil Counts.Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy.Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
P2860
Q26829834-4DDBFC1C-78D6-4058-AC12-C4E1E05E6117Q33414659-BDB2F0C3-7943-4ABE-A7A3-DA07BA02EE5BQ33416472-32423B35-23D7-4BD9-8ACE-428D6D8D1D28Q33770736-687B92FB-AA0C-4D44-A648-4421B319AA89Q35044368-41D9D5F2-9778-4030-AC50-33EB573CD07DQ35085493-304C0F04-D9A3-4CC5-946C-268A9571668CQ36348464-671B2C02-C4C4-44E5-A70E-70CC8E6C0300Q36497905-1E89995D-451E-4CC7-8969-FC35173F36E7Q37931905-26840E1E-4B65-446F-9F2C-E220BF32DCC7Q38068457-3B202BB8-6823-4001-8E66-A4369B6AD81CQ38225700-EEE38355-6503-4496-9A61-69F0A81AE852Q38269589-A7F33217-9F19-49CA-A0C7-9D5873452E7DQ38674714-9F67E6EF-8C61-4C9E-B929-50619D1A941AQ38682028-118B3709-5866-4C8B-9C13-8E66639277C0Q38711166-1A398F2A-89CD-4298-8895-F6EF2DB0F2F2Q38940016-F68CF07E-66B7-4529-9716-87E306BB6B80Q39000902-B646B4F0-DCE1-4B69-BFC1-A3BE6BDDF6CBQ40180945-CECBEAF1-F6D1-45F7-B395-020E2AEA08FDQ40273644-AF284DFE-2188-4491-8C2C-2E237F6FF17CQ44711105-AFFEEAA3-81D9-4049-8F26-6371F6BB5625Q47367758-46F0F5FE-5286-4005-8B1A-C733381C2296Q48273553-AB0E20DD-79D9-4539-B7A3-F541295ABC69Q50878372-A911FD8D-6009-4C52-853F-E924BE6D9780Q51003614-BA812CA5-9BF9-4CED-9987-3581AF1E1C11Q51425302-F560E0DE-9D53-49C8-9326-CE58E4153553Q52805500-D4918156-DD73-4947-8356-D8A59A58EFDCQ55057566-A284DF5E-6036-4C6E-BA52-0A337F11960FQ58767839-BD683A20-FF5E-48BF-A5FE-945B0611EE2F
P2860
Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prophylaxis of chemotherapy-in ...... ing factors: where are we now?
@ast
Prophylaxis of chemotherapy-in ...... ing factors: where are we now?
@en
type
label
Prophylaxis of chemotherapy-in ...... ing factors: where are we now?
@ast
Prophylaxis of chemotherapy-in ...... ing factors: where are we now?
@en
prefLabel
Prophylaxis of chemotherapy-in ...... ing factors: where are we now?
@ast
Prophylaxis of chemotherapy-in ...... ing factors: where are we now?
@en
P2093
P2860
P1476
Prophylaxis of chemotherapy-in ...... ing factors: where are we now?
@en
P2093
Didier Kamioner
Jeffrey Crawford
Matti Aapro
P2860
P2888
P304
P356
10.1007/S00520-010-0816-Y
P577
2010-02-27T00:00:00Z